BR112014023092A8 - Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit - Google Patents
Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kitInfo
- Publication number
- BR112014023092A8 BR112014023092A8 BR112014023092A BR112014023092A BR112014023092A8 BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8 BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A BR112014023092 A BR 112014023092A BR 112014023092 A8 BR112014023092 A8 BR 112014023092A8
- Authority
- BR
- Brazil
- Prior art keywords
- hpv
- immunogenic composition
- disease
- infection
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIÇÃO IMUNOGÊNICA, MÉTODO PARA A PREVENÇÃO DE INFECÇÃO OU DOENÇA POR HPV EM UM INDIVÍDUO, E, KIT. A revelação fornece composições imunogênicas compreendendo VLPs do HPV de um ou mais tipos de HPV em combinação com um adjuvante compreendendo um agonista TLR para uso em um método para a prevenção de infecção ou doença por HPV em um indivíduo, em que uma primeira dose da composição imunogênica compreendendo VLPs do HPV e um agonista TLR é administrada, seguida por uma segunda dose de uma composição imunogênica compreendendo VLPs do HPV de um ou mais tipos de HPV, mas que não compreende um agonista TLR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612345P | 2012-03-18 | 2012-03-18 | |
PCT/EP2013/055582 WO2013139744A1 (en) | 2012-03-18 | 2013-03-18 | Method of vaccination against human papillomavirus |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014023092A2 BR112014023092A2 (pt) | 2017-06-20 |
BR112014023092A8 true BR112014023092A8 (pt) | 2017-07-25 |
Family
ID=47913410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014023092A BR112014023092A8 (pt) | 2012-03-18 | 2013-03-18 | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150110824A1 (pt) |
EP (1) | EP2827891A1 (pt) |
JP (1) | JP2015514696A (pt) |
CN (1) | CN104203270A (pt) |
BR (1) | BR112014023092A8 (pt) |
CA (1) | CA2866582A1 (pt) |
WO (1) | WO2013139744A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
MY195018A (en) | 2014-10-24 | 2023-01-03 | Hpvvax Llc | Cancer and skin lesion treatment |
BR112018067550A2 (pt) * | 2016-02-27 | 2019-10-01 | Hpvvax Llc | métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica |
EP3458475B1 (en) | 2016-05-16 | 2022-07-27 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DE122007000019I1 (de) | 1991-07-19 | 2007-07-26 | Univ Queensland | Impfstoffen gegen Papillomavirus |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
CA2157932C (en) | 1993-03-09 | 2011-10-11 | Robert C. Rose | Production of human papillomavirus capsid protein and virus-like particles |
ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
HU219810B (hu) | 1993-11-17 | 2001-08-28 | Deutsche Om Arzneimittel Gmbh. | Glükózamin-diszacharidok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, valamint alkalmazásuk |
EP1728800A1 (de) | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
IL117459A (en) | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
ES2572628T3 (es) | 1997-09-05 | 2016-06-01 | Medimmune, Inc. | Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP) |
US6060324A (en) | 1997-11-12 | 2000-05-09 | Phytochem Technologies, Inc. | Fluorometric assay composition for measurement of antioxidant activity |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
HUP0102332A3 (en) | 1998-06-08 | 2002-11-28 | Sca Emballage France | Fast flattening packaging |
CN1168702C (zh) | 1998-06-30 | 2004-09-29 | Om药业 | 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物 |
PL201482B1 (pl) | 1998-10-16 | 2009-04-30 | Smithkline Beecham Biolog | Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
ATE404561T1 (de) | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
AU2002343728A1 (en) | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
CN1234851C (zh) * | 2003-01-30 | 2006-01-04 | 上海天甲生物医药有限公司 | 抗人***状瘤病毒疫苗 |
SG177269A1 (en) | 2009-06-25 | 2012-02-28 | Glaxosmithkline Biolog Sa | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease |
-
2013
- 2013-03-18 US US14/385,813 patent/US20150110824A1/en not_active Abandoned
- 2013-03-18 JP JP2014561480A patent/JP2015514696A/ja active Pending
- 2013-03-18 BR BR112014023092A patent/BR112014023092A8/pt not_active IP Right Cessation
- 2013-03-18 EP EP13711019.3A patent/EP2827891A1/en not_active Withdrawn
- 2013-03-18 CA CA 2866582 patent/CA2866582A1/en not_active Abandoned
- 2013-03-18 WO PCT/EP2013/055582 patent/WO2013139744A1/en active Application Filing
- 2013-03-18 CN CN201380014959.4A patent/CN104203270A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112014023092A2 (pt) | 2017-06-20 |
JP2015514696A (ja) | 2015-05-21 |
CN104203270A (zh) | 2014-12-10 |
EP2827891A1 (en) | 2015-01-28 |
CA2866582A1 (en) | 2013-09-26 |
WO2013139744A1 (en) | 2013-09-26 |
US20150110824A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000331A1 (es) | Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal. | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
UY36422A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
BRPI1013780A2 (pt) | composições para imunização contra staphylococcus aureus. | |
BR212012031500U2 (pt) | composições sólidas | |
BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
BR112015015870A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
BR112015004515A2 (pt) | composição imunogênica | |
BR112017000519A2 (pt) | "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica" | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
BR112015017241A8 (pt) | composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |